These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 31124388)
1. Physico-chemical stability of co-formulation of PEGylated human amylin with insulin. Sinésia C; do Nascimento CVMF; Lacativa PGS; Lima LMTR Pharm Dev Technol; 2019 Oct; 24(8):975-981. PubMed ID: 31124388 [TBL] [Abstract][Full Text] [Related]
2. Physico-chemical properties of co-formulated fast-acting insulin with pramlintide. da Silva DC; Lima LMTR Int J Pharm; 2018 Aug; 547(1-2):621-629. PubMed ID: 29928940 [TBL] [Abstract][Full Text] [Related]
7. Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. Gingell JJ; Burns ER; Hay DL Endocrinology; 2014 Jan; 155(1):21-6. PubMed ID: 24169554 [TBL] [Abstract][Full Text] [Related]
10. Amylin conjugation with methoxyl polyethyleneglycol. Guterres MF; Guerreiro LH; Melo-Ferreira B; Erthal LC; Lima LM Protein Pept Lett; 2013 Nov; 20(11):1264-71. PubMed ID: 23855659 [TBL] [Abstract][Full Text] [Related]
11. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Owens DR; Bolli GB Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209 [TBL] [Abstract][Full Text] [Related]
12. Effects of amylin and the amylin agonist pramlintide on glucose metabolism. Schmitz O; Nyholm B; Orskov L; Gravholt C; Møller N Diabet Med; 1997 Jun; 14 Suppl 2():S19-23. PubMed ID: 9212325 [TBL] [Abstract][Full Text] [Related]
13. The quaternary structure of insulin glargine and glulisine under formulation conditions. Nagel N; Graewert MA; Gao M; Heyse W; Jeffries CM; Svergun D; Berchtold H Biophys Chem; 2019 Oct; 253():106226. PubMed ID: 31376619 [TBL] [Abstract][Full Text] [Related]
14. A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs. Maikawa CL; Smith AAA; Zou L; Roth GA; Gale EC; Stapleton LM; Baker SW; Mann JL; Yu AC; Correa S; Grosskopf AK; Liong CS; Meis CM; Chan D; Troxell M; Maahs DM; Buckingham BA; Webber MJ; Appel EA Nat Biomed Eng; 2020 May; 4(5):507-517. PubMed ID: 32393892 [TBL] [Abstract][Full Text] [Related]
15. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Weyer C; Maggs DG; Young AA; Kolterman OG Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273 [TBL] [Abstract][Full Text] [Related]
16. Development of Cagrilintide, a Long-Acting Amylin Analogue. Kruse T; Hansen JL; Dahl K; Schäffer L; Sensfuss U; Poulsen C; Schlein M; Hansen AMK; Jeppesen CB; Dornonville de la Cour C; Clausen TR; Johansson E; Fulle S; Skyggebjerg RB; Raun K J Med Chem; 2021 Aug; 64(15):11183-11194. PubMed ID: 34288673 [TBL] [Abstract][Full Text] [Related]
17. Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms. Frigori RB Phys Chem Chem Phys; 2017 Sep; 19(37):25617-25633. PubMed ID: 28905065 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Adler BL; Yarchoan M; Hwang HM; Louneva N; Blair JA; Palm R; Smith MA; Lee HG; Arnold SE; Casadesus G Neurobiol Aging; 2014 Apr; 35(4):793-801. PubMed ID: 24239383 [TBL] [Abstract][Full Text] [Related]
19. PEGylated prodrugs of antidiabetic peptides amylin and GLP-1. Böttger R; Knappe D; Hoffmann R J Control Release; 2018 Dec; 292():58-66. PubMed ID: 29729352 [TBL] [Abstract][Full Text] [Related]
20. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]